Beijing Dongfang Biotech Co., Ltd.

Quick facts

Phase 3 pipeline

• Exendin-4 Fc fusion protein injection · Diabetes
  Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose.

Phase 1 pipeline

• JY09

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Beijing Dongfang Biotech Co., Ltd. portfolio CI brief
• Beijing Dongfang Biotech Co., Ltd. pipeline updates RSS